Johannes H Schulte researcher
Schulte, Johannes Hubertus 1978-
VIAF ID: 75062269 (Personal)
Permalink: http://viaf.org/viaf/75062269
Preferred Forms
4xx's: Alternate Name Forms (3)
5xx's: Related Names (2)
- 510 2 _
‡a
Klinik für Kinderheilkunde I
‡g
Essen
‡4
affi
‡4
https://d-nb.info/standards/elementset/gnd#affiliation
‡e
Affiliation
- 510 2 _
‡a
Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie
‡4
affi
‡4
https://d-nb.info/standards/elementset/gnd#affiliation
‡e
Affiliation
Works
Title | Sources |
---|---|
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Euro |
![]() |
Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature |
![]() |
Analyse Neurotrophinrezeptor-vermittelter Genregulationsmuster in neuroblastischen Tumoren |
![]() |
The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia. |
![]() |
Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma |
![]() |
Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma |
![]() |
Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome |
![]() |
IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma. |
![]() |
The landscape of genomic alterations across childhood cancers. |
![]() |
Lin28B and Let-7 in the Control of Sympathetic Neurogenesis and Neuroblastoma Development |
![]() |
Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification |
![]() |
miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin |
![]() |
miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples |
![]() |
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells |
![]() |
MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma |
![]() |
Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance |
![]() |
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations |
![]() |
Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions |
![]() |
Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment |
![]() |
WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma |
![]() |